Generic Name and Formulations:
Acrivastine 8mg, pseudoephedrine HCl 60mg; caps.
- Dysphagia Due to MS Associated With Reduced Swallowing-Related QoL
- Criteria for Early-Stage Parkinson Disease to Be Used in Clinical Trials
- Hypertension and Heart Disease May Contribute to Brain Atrophy in MS
Indications for SEMPREX-D:
Seasonal allergic rhinitis symptoms.
1 cap every 4–6hrs; max 4 caps/day.
Severe hypertension or coronary artery disease. During or within 14 days of MAOIs.
Hypertension. Diabetes. Ischemic heart disease. Increased intraocular pressure. Hyperthyroidism. Prostatic hypertrophy. Peptic ulcer. GI obstruction. Renal impairment (CrCl ≤48mL/minute): not recommended. Elderly. Pregnancy (Cat.B). Nursing mothers.
Antihistamine + sympathomimetic.
See Contraindications. Avoid concomitant CNS depressants, OTC antihistamines and decongestants, alcohol. Potentiated by beta agonists. Antagonizes antihypertensives.
Somnolence, dry mouth, nervousness, insomnia, ephedrine-like reactions (tachycardia, palpitations, headache, dizziness, nausea).
Neurology Advisor Articles
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- Gender and Multiple Sclerosis: How It Influences Prognosis and Future Treatment
- Drug Prices Increase More Than Expected After Shortages
- Potentially Inappropriate Opioid Prescribing Tied to Overdose
- Loss of Function Variants in LRKK1 and LRKK2 Not Linked to Parkinson Disease
- Scribes Improve Physician Workflow, Patient Interaction